k141_73582_1	SARG|gb|APB03219.1|ARO:3003986|TaeA	27.2	272	405	648	1.17e-07	52.8
k141_404348_5	megares|MEG_2865|Drugs|Phenicol|Chloramphenicol_hydrolase|ESTD_1	34.7	271	365	310	2.31e-42	149
k141_404348_5	NCBI|WP_011906899.1|1|1|estDL136|estDL136||2|CHLORAMPHENICOL/FLORFENICOL|PHENICOL|phenicol_hydrolase|AMR|phenicol	37.3	212	365	308	3.99e-35	129
k141_276505_1	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	30.2	570	740	1033	2.05e-70	248
k141_276505_1	SARG|gb|AEY83581|ARO:3000510|mupB	30.2	570	740	1033	2.05e-70	248
k141_276505_1	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	29.1	573	740	1024	4.41e-67	238
k141_276505_1	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	29.1	573	740	1024	4.41e-67	238
k141_276505_1	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	29.1	573	740	1024	6.01e-67	238
k141_276505_1	SARG|gb|CAA53189|ARO:3000521|mupA	29.1	573	740	1024	6.01e-67	238
k141_276505_1	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	26.4	629	740	1107	2.24e-45	174
k141_276505_1	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	26.4	629	740	1107	2.24e-45	174
k141_56156_1	SARG|YP_594556	22.6	659	685	639	1.54e-42	162
k141_258540_2	SARG|AUI09862.1	45.8	131	549	287	4.55e-26	107
k141_258540_2	SARG|gi|486033774|ref|WP_001505252.1|	38.5	143	549	271	1.57e-23	99.4
k141_258540_2	SARG|gi|490067892|ref|WP_003970071.1|	38.5	143	549	271	2.14e-23	99.0
k141_258540_2	SARG|AJ459418.gene.p01	39.2	125	549	263	1.15e-22	96.7
k141_258540_2	SARG|gi|836556079|ref|WP_047715692.1|	37.4	139	549	271	1.34e-22	96.7
k141_258540_2	SARG|gi|691032885|ref|WP_031987899.1|	37.8	143	549	271	1.34e-22	96.7
k141_258540_2	SARG|gi|916164813|ref|WP_050960181.1|	37.8	143	549	271	1.34e-22	96.7
k141_258540_2	SARG|gi|487670925|ref|WP_001756235.1|	37.8	143	549	271	1.82e-22	96.3
k141_258540_2	SARG|DQ464881.1.gene2.p01	37.8	143	549	271	1.82e-22	96.3
k141_258540_2	NCBI|WP_001043265.1|1|1|sul2|sul2|insensitivity|2|sulfonamide|sulfonamide|sulfonamide-resistant_dihydropteroate_synthase_Sul2|AMR|sulfonamide	37.8	143	549	271	1.82e-22	96.3
k141_129707_1	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	37.7	342	325	703	7.11e-67	221
k141_166938_4	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	30.6	235	237	231	9.44e-29	107
k141_166938_4	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	30.6	235	237	231	9.44e-29	107
k141_166938_4	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	29.5	234	237	239	8.59e-28	105
k141_166938_4	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	30.1	229	237	219	9.16e-25	96.7
k141_166938_4	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	30.1	229	237	219	1.28e-24	96.3
k141_166938_4	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	30.1	229	237	220	1.31e-24	96.3
k141_166938_4	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	30.1	229	237	220	1.83e-24	95.9
k141_166938_4	CARD|gb|ATC67679.1|ARO:3000838|arlR	29.1	230	237	219	6.88e-24	94.4
k141_166938_4	CARD|gb|ADM92605.1|ARO:3000553|adeR	30.8	234	237	247	8.73e-24	94.7
k141_166938_4	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	29.3	229	237	220	2.79e-22	90.1
k141_167797_1	SARG|gb|APB03219.1|ARO:3003986|TaeA	37.0	413	416	648	1.52e-82	265
k141_167797_1	SARG|X63451.gene.p01	32.9	447	416	550	7.57e-53	184
k141_167797_1	megares|MEG_6558|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|SRMB_1	32.9	447	416	550	7.57e-53	184
k141_167797_1	SARG|M80346.gene.p01	33.3	438	416	551	4.00e-50	176
k141_167797_1	megares|MEG_1491|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|CARA_1	33.3	438	416	551	4.00e-50	176
k141_167797_1	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.4	411	416	655	4.20e-48	172
k141_167797_1	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.4	411	416	655	4.20e-48	172
k141_167797_1	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.4	411	416	655	7.98e-48	172
k141_167797_1	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.4	411	416	655	7.98e-48	172
k141_167797_1	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.4	411	416	655	7.98e-48	172
k141_167797_3	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	27.8	216	244	307	2.84e-16	75.5
k141_168300_2	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	25.6	359	601	1033	9.60e-17	83.2
k141_168300_2	SARG|gb|AEY83581|ARO:3000510|mupB	25.6	359	601	1033	9.60e-17	83.2
k141_168300_2	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	24.0	375	601	1024	1.26e-13	73.2
k141_168300_2	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	24.0	375	601	1024	1.26e-13	73.2
k141_168300_2	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	24.0	375	601	1024	1.26e-13	73.2
k141_168300_2	SARG|gb|CAA53189|ARO:3000521|mupA	24.0	375	601	1024	1.26e-13	73.2
k141_168300_2	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	28.6	196	601	1107	1.40e-06	50.4
k141_168300_2	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	28.6	196	601	1107	1.40e-06	50.4
k141_59477_1	megares|MEG_5148|Drugs|beta-lactam|Class_D_betalactamases|OXA_1	74.4	39	143	346	2.44e-14	67.4
k141_59477_6	megares|MEG_7563|Drugs|Glycopeptide|VanB-type_resistance_protein|VANXB_2	32.6	353	358	451	9.34e-40	145
k141_23669_5	CARD|gb|AAN28945.1|ARO:3003785|Ctra_murA_FOF	35.4	435	424	444	5.52e-62	206
k141_262218_3	SARG|gi|542061059|gb|ERI11611.1|	32.6	221	302	316	6.66e-27	106
k141_262218_3	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	34.6	214	302	293	2.29e-26	104
k141_262218_3	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	33.5	251	302	307	7.82e-26	103
k141_262218_3	SARG|gi|500194536|ref|WP_011867743.1|	31.2	231	302	306	5.29e-24	98.2
k141_390992_3	SARG|gb|APB03219.1|ARO:3003986|TaeA	31.4	159	476	648	8.54e-11	63.2
k141_390992_3	SARG|gb|MBW0764195.1|ARO:3007027|salC	26.5	155	476	541	8.26e-08	53.5
k141_390992_3	SARG|gi|488243106|ref|WP_002314314.1|	27.6	145	476	492	3.15e-07	51.6
k141_390992_3	SARG|gi|488321355|ref|WP_002390740.1|	26.9	145	476	492	1.68e-06	49.3
k141_390992_3	SARG|gi|488231473|ref|WP_002302681.1|	26.9	145	476	492	1.68e-06	49.3
k141_390992_3	SARG|gi|488216250|ref|WP_002287458.1|	26.9	145	476	492	1.68e-06	49.3
k141_390992_3	SARG|gi|488247627|ref|WP_002318835.1|	26.9	145	476	492	1.68e-06	49.3
k141_390992_3	SARG|AY004350.gene.p01	26.9	145	476	492	1.68e-06	49.3
k141_336102_3	NCBI|WP_012779617.1|1|1|dfrK|dfrK|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrK|AMR|diaminopyrimidine	36.0	136	141	163	6.37e-28	100
k141_336102_3	SARG|gb|CBL80435.1|ARO:3002869|dfrK	34.6	136	141	163	9.00e-28	99.8
k141_336102_3	NCBI|WP_031775848.1|1|1|dfrK|dfrK|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrK|AMR|diaminopyrimidine	34.6	136	141	163	9.00e-28	99.8
k141_336102_3	megares|MEG_2576|Drugs|Trimethoprim|Dihydrofolate_reductase|DFRD_1	37.1	143	141	154	1.13e-26	96.7
k141_336102_3	SARG|gb|AAA85213.1|ARO:3002866|dfrD	37.1	143	141	162	1.40e-26	96.7
k141_336102_3	megares|MEG_2575|Drugs|Trimethoprim|Dihydrofolate_reductase|DFRD_1	37.1	143	141	162	1.40e-26	96.7
k141_336102_3	megares|MEG_2574|Drugs|Trimethoprim|Dihydrofolate_reductase|DFRD_1	37.1	143	141	166	1.55e-26	96.7
k141_336102_3	SARG|gb|BAE15963.1|ARO:3002868|dfrG	38.9	108	141	165	4.78e-25	92.8
k141_336102_3	NCBI|WP_000781812.1|1|1|dfrA51|dfrA51|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA51|AMR|diaminopyrimidine	50.0	104	141	158	7.99e-25	92.0
k141_336102_3	NCBI|WP_130949671.1|1|1|dfrA50|dfrA50|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA50|AMR|diaminopyrimidine	40.1	137	141	158	1.27e-23	89.0
k141_24873_3	SARG|gb|AAV85982.1|ARO:3000535|macB	42.1	209	269	644	5.83e-37	137
k141_24873_3	SARG|gi|695840638|ref|WP_032753940.1|	35.0	243	269	646	3.52e-35	132
k141_24873_3	SARG|gi|556492128|ref|WP_023339842.1|	35.0	243	269	646	4.82e-35	131
k141_24873_3	SARG|gi|696368937|ref|WP_032943949.1|	36.4	228	269	648	4.86e-35	131
k141_24873_3	SARG|gi|851913025|ref|WP_048215946.1|	36.4	228	269	648	4.86e-35	131
k141_24873_3	SARG|gi|489930965|ref|WP_003834285.1|	36.4	228	269	648	4.86e-35	131
k141_24873_3	SARG|gi|696361545|ref|WP_032936694.1|	36.4	228	269	648	6.65e-35	131
k141_24873_3	SARG|gi|489936909|ref|WP_003840216.1|	36.4	228	269	648	6.65e-35	131
k141_24873_3	SARG|gi|507079862|ref|WP_016150620.1|	36.4	228	269	648	6.65e-35	131
k141_24873_3	SARG|gi|949791377|ref|WP_057104572.1|	36.4	228	269	648	6.65e-35	131
k141_373305_1	CARD|gb|BAD59497.1|ARO:3000501|rpoB2	55.2	978	979	1162	0.0	1031
k141_373305_1	CARD|gb|WP_041777404.1|ARO:3004480|Bado_rpoB_RIF	54.5	989	979	1186	0.0	1015
k141_373305_1	megares|MEG_8674|Drugs|Rifampin|Rifampin-resistant_beta-subunit_of_RNA_polymerase_RpoB|RPOB_1	54.5	989	979	1186	0.0	1015
k141_318472_2	SARG|gb|AAV85982.1|ARO:3000535|macB	29.3	229	272	644	1.79e-20	89.7
k141_62097_1	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	35.8	204	225	255	1.89e-35	125
k141_62097_1	SARG|gb|AYV52072.1|ARO:3002882|lmrD	33.5	188	225	664	1.78e-23	97.1
k141_62097_1	megares|MEG_4383|Drugs|Tetracycline|Tetracycline_resistance_ABC_efflux_pumps|OTRC_1	29.3	208	225	351	1.76e-15	73.2
k141_62097_1	SARG|gb|AAR96051.1|ARO:3002894|otrC	29.3	208	225	351	2.40e-15	72.8
k141_62097_1	SARG|gb|AAC75271.1|ARO:3003952|yojI	29.9	194	225	547	2.68e-15	73.2
k141_62097_1	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	31.7	208	225	579	6.79e-15	72.0
k141_62097_1	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	32.6	187	225	579	2.28e-14	70.5
k141_116517_2	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	44.3	228	235	231	4.68e-55	175
k141_116517_2	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	43.2	227	235	232	5.46e-54	172
k141_116517_2	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	43.2	227	235	232	5.46e-54	172
k141_116517_2	NCBI|WP_063856715.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	41.9	229	235	232	9.89e-52	166
k141_116517_2	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	42.6	230	235	228	3.52e-51	165
k141_116517_2	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	41.5	234	235	232	3.95e-51	165
k141_116517_2	NCBI|WP_023043165.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	41.5	229	235	232	5.59e-51	164
k141_116517_2	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	41.5	229	235	232	1.12e-50	164
k141_116517_2	NCBI|WP_063856727.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	40.6	229	235	232	1.58e-50	163
k141_116517_2	NCBI|WP_023042613.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	40.6	229	235	232	2.23e-50	163
k141_116517_3	NCBI|WP_063856743.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	35.9	326	479	361	1.52e-55	188
k141_116517_3	megares|MEG_7499|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	35.9	326	479	361	1.52e-55	188
k141_116517_3	NCBI|WP_002305818.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	33.3	345	479	384	2.71e-55	188
k141_116517_3	megares|MEG_7454|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	33.3	345	479	384	2.71e-55	188
k141_116517_3	megares|MEG_7502|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	35.6	326	479	361	8.13e-55	186
k141_116517_3	NCBI|WP_063856733.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	35.6	326	479	361	8.13e-55	186
k141_116517_3	megares|MEG_7487|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	33.0	345	479	386	1.09e-54	186
k141_116517_3	NCBI|WP_063856740.1|1|1|vanS-Pt2|vanS-Pt2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt2|AMR|glycopeptide	33.0	345	479	386	1.09e-54	186
k141_116517_3	megares|MEG_7521|Drugs|Glycopeptide|VanN-type_regulator|VANSN_1	33.3	366	479	364	1.23e-54	186
k141_116517_3	NCBI|WP_063856749.1|1|1|vanS-N|vanS-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-N|AMR|glycopeptide	33.3	366	479	364	1.23e-54	186
k141_264415_1	SARG|gb|AAK76137.1|ARO:3000024|patA	28.8	191	236	564	1.55e-11	62.4
k141_264415_2	SARG|gi|919943616|ref|WP_052915800.1|	34.0	241	414	648	2.06e-22	98.6
k141_264415_2	SARG|gi|766974935|ref|WP_044866868.1|	34.0	241	414	648	2.06e-22	98.6
k141_264415_2	SARG|gi|446110333|ref|WP_000188188.1|	34.0	241	414	648	2.06e-22	98.6
k141_264415_2	SARG|gi|446110308|ref|WP_000188163.1|	34.0	241	414	648	2.76e-22	98.2
k141_264415_2	SARG|gi|446110334|ref|WP_000188189.1|	33.6	241	414	648	2.76e-22	98.2
k141_264415_2	SARG|gi|446110269|ref|WP_000188124.1|	33.6	241	414	648	2.76e-22	98.2
k141_264415_2	SARG|YP_002328441	33.6	241	414	648	2.76e-22	98.2
k141_264415_2	SARG|gi|545167026|ref|WP_021521592.1|	33.6	241	414	648	3.70e-22	97.8
k141_264415_2	SARG|gi|971845730|ref|WP_058914924.1|	34.0	241	414	648	3.70e-22	97.8
k141_264415_2	SARG|gi|693054987|ref|WP_032223114.1|	34.0	241	414	648	3.70e-22	97.8
k141_356031_4	megares|MEG_727|Drugs|beta-lactam|Class_C_betalactamases|AMPC_1	39.2	403	425	415	4.43e-99	301
k141_99355_1	CARD|gb|AEX49906.1|ARO:3003583|basS	34.8	230	477	477	3.63e-27	112
k141_99355_1	SARG|gb|AAG05187.1|ARO:3005067|ParS	28.2	284	477	428	7.24e-25	105
k141_99355_1	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	25.7	206	477	359	9.29e-18	83.6
k141_99355_1	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	22.6	226	477	364	3.52e-14	72.8
k141_99355_1	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	22.6	226	477	364	3.52e-14	72.8
k141_117223_3	SARG|gi|947982677|ref|WP_056642336.1|	32.1	554	552	626	3.04e-89	286
k141_117223_3	SARG|gi|948137056|ref|WP_056795395.1|	31.3	556	552	602	4.68e-89	285
k141_117223_3	SARG|gi|639892676|ref|WP_024755698.1|	31.9	554	552	631	9.45e-89	285
k141_117223_3	SARG|gi|695842130|ref|WP_032755430.1|	31.7	556	552	603	1.86e-88	283
k141_117223_3	SARG|gi|505420018|ref|WP_015607120.1|	31.7	556	552	603	2.61e-88	283
k141_117223_3	SARG|gi|648667297|ref|WP_026359044.1|	31.0	552	552	605	7.55e-88	282
k141_117223_3	SARG|gi|664042835|ref|WP_030582300.1|	31.3	556	552	604	1.45e-87	281
k141_117223_3	SARG|gi|663155409|ref|WP_030194633.1|	30.9	557	552	605	1.49e-87	281
k141_117223_3	SARG|gi|664538723|ref|WP_031054357.1|	30.9	557	552	605	1.49e-87	281
k141_117223_3	SARG|gi|663330365|ref|WP_030329892.1|	30.9	557	552	607	1.56e-87	281
k141_320153_3	SARG|NC_002951.3238155.p01	28.0	404	460	465	9.25e-38	142
k141_320153_3	SARG|NC_002951.3237948.p01	29.1	419	460	643	5.17e-36	139
k141_320153_3	SARG|NC_002951.3237419.p01	26.8	455	460	480	1.85e-35	136
k141_320153_3	SARG|NC_009641.5331418.p01	27.2	389	460	452	3.27e-35	135
k141_155460_2	megares|MEG_7572|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_5	29.3	365	331	359	7.26e-24	99.4
k141_155460_2	NCBI|WP_015943583.1|1|1|vanI|vanI|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-alanine--(R)-lactate_ligase_VanI|AMR|glycopeptide	28.0	364	331	341	2.06e-23	97.8
k141_155460_2	SARG|gi|447002588|ref|WP_001079844.1|	31.5	270	331	343	7.52e-23	96.3
k141_155460_2	SARG|gi|726981187|ref|WP_033585865.1|	30.9	269	331	340	9.93e-23	95.9
k141_155460_2	SARG|gi|726976857|ref|WP_033582037.1|	30.9	269	331	340	9.93e-23	95.9
k141_155460_2	SARG|gi|751653785|ref|WP_041120633.1|	30.9	269	331	343	1.03e-22	95.9
k141_155460_2	SARG|ACP19236	30.9	269	331	343	1.03e-22	95.9
k141_155460_2	SARG|NP_878016	30.9	269	331	343	1.03e-22	95.9
k141_155460_2	SARG|gi|309385870|gb|ADO66795.1|	30.9	269	331	359	1.25e-22	95.9
k141_155460_2	SARG|gi|670466158|ref|WP_031414935.1|	26.4	363	331	343	2.67e-22	94.7
k141_247772_1	SARG|gb|WP_104671188.1|ARO:3003948|efrA	47.4	228	232	575	1.68e-67	216
k141_247772_1	SARG|gb|AAK76137.1|ARO:3000024|patA	41.7	223	232	564	1.19e-50	172
k141_247772_1	SARG|gi|764446018|ref|WP_044369325.1|	44.2	208	232	605	7.87e-50	170
k141_247772_1	SARG|gi|772774655|ref|WP_045322518.1|	41.8	225	232	620	1.32e-49	170
k141_247772_1	SARG|gi|1011969930|ref|WP_062776015.1|	43.8	226	232	601	1.45e-49	169
k141_247772_1	SARG|gi|799286378|ref|WP_045936958.1|	41.3	225	232	620	1.83e-49	169
k141_247772_1	SARG|gi|917127754|ref|WP_051734466.1|	41.3	225	232	620	1.83e-49	169
k141_247772_1	SARG|gi|926294973|ref|WP_053631154.1|	41.3	225	232	620	1.83e-49	169
k141_247772_1	SARG|gi|695842130|ref|WP_032755430.1|	43.8	208	232	603	2.06e-49	169
k141_247772_1	SARG|gi|695865802|ref|WP_032778631.1|	43.8	208	232	605	2.12e-49	169
k141_247772_2	SARG|gb|CDO61516.1|ARO:3003949|efrB	42.8	278	497	362	5.76e-72	231
k141_247772_2	SARG|gb|AAK76136.1|ARO:3000025|patB	29.2	435	497	588	1.41e-54	191
k141_247772_2	SARG|gb|AYV52072.1|ARO:3002882|lmrD	29.1	440	497	664	6.68e-50	180
k141_247772_2	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	26.2	485	497	579	1.06e-49	178
k141_247772_2	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	27.8	486	497	579	1.94e-48	174
k141_247772_2	SARG|gb|WP_104671188.1|ARO:3003948|efrA	27.4	481	497	575	7.67e-45	164
k141_247772_2	SARG|gi|497748188|ref|WP_010062372.1|	28.1	480	497	605	2.90e-44	163
k141_247772_2	SARG|gi|827013130|ref|WP_047175495.1|	27.5	477	497	603	1.38e-43	161
k141_247772_2	SARG|gi|664170108|ref|WP_030704355.1|	27.3	477	497	603	1.89e-43	161
k141_247772_2	SARG|gi|764446018|ref|WP_044369325.1|	27.9	480	497	605	1.93e-43	161
k141_156081_1	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	36.9	65	65	232	1.95e-11	55.5
k141_156081_1	CARD|gb|ATC67679.1|ARO:3000838|arlR	43.3	60	65	219	6.53e-11	53.9
k141_156081_1	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.5	63	65	231	2.65e-10	52.4
k141_156081_1	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.5	63	65	231	3.67e-10	52.0
k141_156081_1	CARD|gb|AAG06465.1|ARO:3005063|cprR	41.5	65	65	223	4.82e-10	51.6
k141_156081_1	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.1	61	65	231	1.35e-09	50.4
k141_156081_1	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.1	61	65	231	1.35e-09	50.4
k141_156081_1	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	32.3	65	65	231	4.93e-09	48.9
k141_156081_1	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.4	65	65	219	6.39e-09	48.5
k141_156081_1	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.4	65	65	219	6.39e-09	48.5
k141_45468_3	SARG|gb|MBY8651254.1|ARO:3007188|vanH_in_vanP_cl	32.3	229	317	314	6.40e-31	117
k141_45468_3	SARG|gi|740152780|ref|WP_037997109.1|	28.4	299	317	322	2.01e-29	113
k141_45468_3	SARG|FJ349556.1.gene5.p01	27.6	319	317	326	7.74e-27	106
k141_45468_3	SARG|YP_002333394	26.3	297	317	323	1.02e-26	106
k141_45468_3	SARG|DQ018711.1.gene4.p01	27.2	301	317	322	1.39e-26	105
k141_45468_3	SARG|AF155139.2.gene6.p01	26.8	295	317	322	2.66e-26	105
k141_45468_3	SARG|NP_878015	28.8	274	317	322	2.66e-26	105
k141_45468_3	SARG|gi|738848198|ref|WP_036737307.1|	26.9	301	317	323	7.16e-26	103
k141_45468_3	SARG|gi|746609237|ref|WP_039635344.1|	27.9	283	317	322	9.75e-26	103
k141_45468_3	SARG|gi|737310392|ref|WP_035293250.1|	26.9	301	317	323	1.89e-25	102
k141_9426_1	SARG|gb|WP_104671188.1|ARO:3003948|efrA	43.9	508	773	575	1.48e-123	381
k141_9426_1	SARG|gb|AAK76137.1|ARO:3000024|patA	33.1	507	773	564	3.03e-85	280
k141_9426_1	SARG|gi|930482089|ref|WP_054228897.1|	35.8	360	773	599	1.17e-59	211
k141_9426_1	SARG|gi|985844137|ref|WP_060895163.1|	35.8	360	773	599	1.17e-59	211
k141_9426_1	SARG|gi|664244930|ref|WP_030776974.1|	34.7	377	773	601	1.21e-59	211
k141_9426_1	SARG|gi|1011969930|ref|WP_062776015.1|	35.0	377	773	601	2.29e-59	211
k141_9426_1	SARG|gi|943896259|ref|WP_055534530.1|	34.7	377	773	601	2.29e-59	211
k141_9426_1	SARG|gi|928900436|ref|WP_053931243.1|	29.8	523	773	600	8.02e-59	209
k141_9426_1	SARG|gi|664579989|ref|WP_031094015.1|	29.8	523	773	601	8.17e-59	209
k141_9426_1	SARG|gi|664556405|ref|WP_031071225.1|	35.4	376	773	602	1.14e-58	209
k141_9426_2	SARG|gb|AYV52072.1|ARO:3002882|lmrD	37.0	549	600	664	5.48e-116	358
k141_9426_2	SARG|gb|AAK76136.1|ARO:3000025|patB	35.9	576	600	588	1.24e-113	350
k141_9426_2	SARG|gb|CDO61516.1|ARO:3003949|efrB	48.0	344	600	362	1.73e-103	316
k141_9426_2	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	31.9	586	600	579	2.48e-94	300
k141_9426_2	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	32.1	586	600	579	2.87e-92	294
k141_9426_2	SARG|gb|AAC74000.1|ARO:3003950|msbA	34.2	529	600	582	3.10e-92	294
k141_9426_2	SARG|gi|493394434|ref|WP_006350564.1|	34.9	521	600	602	2.28e-83	271
k141_9426_2	SARG|gi|944009777|ref|WP_055601444.1|	34.4	535	600	628	2.99e-83	272
k141_9426_2	SARG|gi|947982677|ref|WP_056642336.1|	34.5	525	600	626	3.99e-83	271
k141_9426_2	SARG|gi|639892676|ref|WP_024755698.1|	34.5	525	600	631	4.48e-83	271
k141_174460_1	SARG|gb|AAK76136.1|ARO:3000025|patB	30.3	561	580	588	2.98e-73	244
k141_174460_1	SARG|gb|AYV52072.1|ARO:3002882|lmrD	30.8	491	580	664	2.06e-66	227
k141_174460_1	SARG|gb|CDO61516.1|ARO:3003949|efrB	33.7	356	580	362	4.11e-59	200
k141_174460_1	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	29.2	490	580	579	1.32e-54	193
k141_174460_1	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	28.8	486	580	579	1.83e-54	193
k141_174460_1	SARG|gb|AAC74000.1|ARO:3003950|msbA	28.9	470	580	582	2.31e-51	184
k141_174460_1	SARG|gi|664556405|ref|WP_031071225.1|	26.5	573	580	602	1.56e-50	182
k141_174460_1	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	27.5	559	580	578	3.88e-50	181
k141_174460_1	SARG|gi|748767925|ref|WP_040019608.1|	27.2	593	580	623	5.03e-49	179
k141_174460_1	SARG|gi|558888514|ref|WP_023543283.1|	27.2	481	580	615	3.02e-48	176
k141_174460_2	SARG|gb|WP_104671188.1|ARO:3003948|efrA	39.8	397	455	575	4.89e-91	286
k141_174460_2	SARG|gb|AAK76137.1|ARO:3000024|patA	36.9	428	455	564	5.96e-81	259
k141_174460_2	SARG|gi|748767925|ref|WP_040019608.1|	47.0	264	455	623	5.01e-72	238
k141_174460_2	SARG|AF170880.4.gene1.p01	44.4	315	455	615	1.63e-71	236
k141_174460_2	SARG|gi|558888514|ref|WP_023543283.1|	44.1	315	455	615	3.18e-71	235
k141_174460_2	SARG|gi|497748188|ref|WP_010062372.1|	46.1	267	455	605	7.39e-70	231
k141_174460_2	SARG|gi|764446018|ref|WP_044369325.1|	46.8	267	455	605	7.39e-70	231
k141_174460_2	SARG|gi|926400371|ref|WP_053728483.1|	46.1	258	455	603	1.39e-69	231
k141_174460_2	SARG|gi|695887424|ref|WP_032788534.1|	46.4	267	455	605	1.44e-69	231
k141_174460_2	SARG|gi|664180077|ref|WP_030714054.1|	46.4	267	455	605	1.44e-69	231
k141_174551_1	NCBI|AKC61310.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	40.0	185	334	552	2.16e-35	134
k141_174551_1	SARG|gb|AHB37625.1|ARO:3004715|vga(E)	39.4	175	334	524	8.21e-35	132
k141_174551_1	SARG|FR772051.1.gene9.p01	39.7	179	334	524	1.44e-33	128
k141_174551_1	SARG|gb|AVI44920.1|ARO:3004470|poxtA	41.3	167	334	542	3.17e-33	127
k141_174551_1	NCBI|WP_209691075.1|1|1|poxtA2|poxtA|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA2|AMR|multidrug	41.3	167	334	544	3.22e-33	127
k141_174551_1	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.2	183	334	655	2.05e-32	126
k141_174551_1	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.2	183	334	655	2.05e-32	126
k141_174551_1	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.2	183	334	655	2.05e-32	126
k141_174551_1	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.2	183	334	655	2.05e-32	126
k141_174551_1	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.2	183	334	655	2.05e-32	126
k141_267365_1	SARG|YP_001571041	45.0	120	279	648	2.69e-23	98.2
k141_267365_1	SARG|gi|960873409|ref|WP_058345546.1|	45.0	120	279	648	2.69e-23	98.2
k141_267365_1	SARG|gi|740610794|ref|WP_038396317.1|	45.0	120	279	648	2.69e-23	98.2
k141_267365_1	SARG|gi|974672242|ref|WP_059256507.1|	43.2	139	279	648	3.65e-23	97.8
k141_267365_1	SARG|gi|974641719|ref|WP_059227752.1|	43.2	139	279	648	3.65e-23	97.8
k141_267365_1	SARG|gi|446110299|ref|WP_000188154.1|	43.2	139	279	648	3.65e-23	97.8
k141_267365_1	SARG|ZP_02903696	43.2	139	279	648	3.65e-23	97.8
k141_267365_1	SARG|gi|974688082|ref|WP_059271287.1|	43.2	139	279	648	3.65e-23	97.8
k141_267365_1	SARG|gi|446048013|ref|WP_000125868.1|	44.7	123	279	648	3.04e-22	95.1
k141_267365_1	SARG|gi|555268037|ref|WP_023249477.1|	44.2	120	279	648	7.52e-22	94.0
k141_102028_1	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	45.9	366	354	703	2.45e-92	289
k141_341688_2	SARG|NP_348076	27.6	675	699	652	3.06e-76	256
k141_341688_2	SARG|L42544.gene.p01	26.6	670	699	651	4.16e-76	256
k141_341688_2	SARG|AAV80410	26.4	670	699	651	2.16e-75	254
k141_341688_2	SARG|YP_002850805	26.5	679	699	652	2.20e-74	251
k141_341688_2	SARG|ZP_02952732	26.6	681	699	652	2.18e-72	246
k141_341688_2	SARG|ZP_02632674	26.6	681	699	660	2.56e-72	246
k141_341688_2	megares|MEG_7175|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	26.9	674	699	639	8.62e-72	244
k141_341688_2	SARG|L20800.gene.p01	26.6	681	699	652	1.55e-71	244
k141_341688_2	megares|MEG_7169|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	27.0	673	699	629	3.61e-71	242
k141_341688_2	ResF|tet(O/W)_3_AM889120_1	27.0	673	699	639	4.43e-71	242
k141_323122_7	SARG|gb|WP_082039181.1|ARO:3007028|salD	27.9	165	230	544	1.10e-06	47.8
k141_323122_7	SARG|gb|WP_096809342.1|ARO:3007029|salE	27.0	215	230	543	1.47e-06	47.4
k141_323122_8	SARG|DQ018711.1.gene4.p01	34.3	251	318	322	1.85e-35	129
k141_323122_8	SARG|gi|746609237|ref|WP_039635344.1|	35.6	236	318	322	3.61e-35	129
k141_323122_8	SARG|YP_002333394	33.9	236	318	323	1.00e-34	127
k141_323122_8	SARG|AF155139.2.gene6.p01	36.0	236	318	322	1.91e-34	127
k141_323122_8	SARG|AF310956.2.gene5.p01	33.5	236	318	323	3.80e-34	126
k141_323122_8	NCBI|WP_063856701.1|1|1|vanH-B|vanH-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-B|AMR|glycopeptide	33.5	236	318	323	3.80e-34	126
k141_323122_8	SARG|gi|740152780|ref|WP_037997109.1|	33.1	236	318	322	1.41e-33	124
k141_323122_8	NCBI|WP_011029109.1|1|1|vanH-Sc|vanH-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Sc|AMR|glycopeptide	32.3	266	318	337	2.63e-33	124
k141_323122_8	SARG|gi|737310392|ref|WP_035293250.1|	33.5	251	318	323	2.79e-33	124
k141_323122_8	SARG|Q47748	33.6	241	318	323	2.04e-32	121
k141_215860_1	SARG|gi|585366847|ref|WP_024248430.1|	33.1	130	961	648	2.25e-06	50.4
k141_215860_1	SARG|gi|585345742|ref|WP_024227362.1|	35.0	123	961	648	2.25e-06	50.4
k141_215860_1	SARG|ZP_03045710	33.1	130	961	648	2.95e-06	50.1
k141_215860_1	SARG|gi|446110349|ref|WP_000188204.1|	33.1	130	961	648	2.95e-06	50.1
k141_215860_1	SARG|gi|1015890335|ref|WP_062865166.1|	33.1	130	961	648	2.95e-06	50.1
k141_215860_1	SARG|gi|446110337|ref|WP_000188192.1|	33.1	130	961	648	2.95e-06	50.1
k141_215860_1	SARG|gi|446110341|ref|WP_000188196.1|	33.1	130	961	648	3.88e-06	49.7
k141_215860_1	SARG|gi|766633902|ref|WP_044806522.1|	32.3	130	961	648	6.71e-06	48.9
k141_215860_1	SARG|gi|928816050|ref|WP_053879097.1|	32.3	130	961	648	8.82e-06	48.5
k141_12276_6	SARG|gi|643601187|ref|WP_025237288.1|	39.5	223	291	648	1.79e-42	153
k141_12276_6	SARG|gi|974628291|ref|WP_059215695.1|	39.5	223	291	648	1.79e-42	153
k141_12276_6	SARG|gi|446110298|ref|WP_000188153.1|	39.5	223	291	648	1.79e-42	153
k141_12276_6	SARG|gi|974633183|ref|WP_059219858.1|	39.5	223	291	648	1.79e-42	153
k141_12276_6	SARG|gi|974684692|ref|WP_059267998.1|	39.5	223	291	648	1.79e-42	153
k141_12276_6	SARG|gi|974672242|ref|WP_059256507.1|	39.5	223	291	648	2.47e-42	152
k141_12276_6	SARG|gi|974641719|ref|WP_059227752.1|	39.5	223	291	648	2.47e-42	152
k141_12276_6	SARG|gi|446110299|ref|WP_000188154.1|	39.5	223	291	648	2.47e-42	152
k141_12276_6	SARG|ZP_02903696	39.5	223	291	648	2.47e-42	152
k141_12276_6	SARG|gi|974688082|ref|WP_059271287.1|	39.5	223	291	648	2.47e-42	152
k141_323772_4	SARG|gb|ABA71733.1|ARO:3002972|vanTG	31.3	380	403	712	4.52e-46	167
k141_323772_4	SARG|AAY67970	31.0	374	403	698	4.19e-43	159
k141_323772_4	SARG|AF162694.1.gene4.p01	31.0	374	403	698	7.85e-43	158
k141_323772_4	SARG|gi|657686198|ref|WP_029487032.1|	31.0	374	403	698	7.85e-43	158
k141_323772_4	SARG|gb|ABX54690.1|ARO:3002974|vanTrL	31.0	368	403	366	5.45e-38	139
k141_323772_4	SARG|FJ872411.1.gene43.p01	31.4	338	403	702	2.71e-35	136
k141_323772_4	NCBI|WP_063856755.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	29.7	370	403	700	5.66e-34	132
k141_323772_4	NCBI|WP_063856756.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	30.4	322	403	700	4.74e-33	130
k141_323772_4	NCBI|WP_063856759.1|1|1|vanTc3|vanTc3|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT|AMR|glycopeptide	28.9	343	403	700	7.19e-32	126
k141_323772_4	NCBI|WP_063856758.1|1|1|vanTc2|vanTc2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT|AMR|glycopeptide	28.8	364	403	706	1.33e-31	125
k141_177754_1	SARG|ZP_03958019	82.8	29	31	317	8.86e-12	55.1
k141_177754_1	SARG|YP_002937728	71.0	31	31	289	1.58e-11	54.3
k141_177754_1	SARG|YP_002929946	79.3	29	31	282	2.14e-11	53.9
k141_177754_1	SARG|ZP_04528247	71.0	31	31	279	4.01e-11	53.1
k141_177754_1	SARG|YP_523088	71.0	31	31	277	9.65e-10	49.3
k141_177754_1	SARG|YP_001696597	67.7	31	31	277	1.33e-09	48.9
k141_177754_1	SARG|ZP_01723236	67.7	31	31	277	1.33e-09	48.9
k141_177754_1	SARG|ZP_02913367	61.3	31	31	273	3.41e-09	47.8
k141_177754_1	SARG|ZP_03552050	67.7	31	31	274	3.42e-09	47.8
k141_177754_1	SARG|YP_997055	64.5	31	31	274	4.69e-09	47.4
k141_224988_6	SARG|gi|445996695|ref|WP_000074550.1|	30.3	221	287	309	5.74e-30	114
k141_224988_6	SARG|gi|507035724|ref|WP_016107411.1|	30.3	221	287	309	3.01e-29	112
k141_224988_6	SARG|gi|445996698|ref|WP_000074553.1|	30.3	221	287	309	3.01e-29	112
k141_224988_6	SARG|gi|542061059|gb|ERI11611.1|	31.4	220	287	316	4.76e-29	111
k141_224988_6	SARG|gi|445996697|ref|WP_000074552.1|	30.3	221	287	309	8.13e-29	110
k141_224988_6	SARG|gi|445996696|ref|WP_000074551.1|	30.3	221	287	309	8.13e-29	110
k141_224988_6	SARG|gi|488067981|ref|WP_002139378.1|	29.2	219	287	309	1.57e-28	110
k141_224988_6	SARG|gi|507050365|ref|WP_016121371.1|	29.2	219	287	309	1.57e-28	110
k141_224988_6	SARG|gi|487936534|ref|WP_002010000.1|	29.2	219	287	309	1.57e-28	110
k141_224988_6	SARG|gi|488130770|ref|WP_002201978.1|	29.2	219	287	309	2.19e-28	109
k141_141715_2	SARG|gb|MBY8651254.1|ARO:3007188|vanH_in_vanP_cl	25.5	263	388	314	7.45e-16	76.6
k141_141715_2	SARG|YP_002333394	25.6	242	388	323	1.29e-13	70.1
k141_141715_2	SARG|gi|498515089|ref|WP_010815296.1|	24.4	242	388	323	1.29e-13	70.1
k141_141715_2	SARG|Q47748	24.4	242	388	323	1.73e-13	69.7
k141_141715_2	SARG|gi|985522333|ref|WP_060811962.1|	24.4	242	388	323	1.73e-13	69.7
k141_141715_2	SARG|AF310956.2.gene5.p01	25.2	242	388	323	4.20e-13	68.6
k141_141715_2	NCBI|WP_063856701.1|1|1|vanH-B|vanH-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-B|AMR|glycopeptide	25.2	242	388	323	4.20e-13	68.6
k141_141715_2	SARG|gb|AAB05626.1|ARO:3002943|vanHB	24.0	242	388	323	4.20e-13	68.6
k141_122487_1	CARD|gb|AAC75429.1|ARO:3000833|evgS	28.1	477	987	1197	4.29e-32	134
k141_122487_1	CARD|gb|AAD51347.1|ARO:3003067|smeS	27.1	262	987	467	4.10e-17	84.3
k141_122487_1	CARD|gb|ADM92606.1|ARO:3000549|adeS	25.6	242	987	361	2.48e-15	77.8
k141_122487_1	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	29.9	134	987	228	4.35e-09	57.0
k141_86339_1	SARG|gi|655413091|ref|WP_028811890.1|	68.9	74	83	603	9.68e-28	103
k141_86339_1	SARG|gi|663330365|ref|WP_030329892.1|	68.9	74	83	607	1.33e-27	102
k141_86339_1	SARG|gi|1033151784|ref|WP_064457526.1|	67.6	74	83	614	1.83e-27	102
k141_86339_1	SARG|gi|987887954|ref|WP_060953374.1|	67.6	74	83	614	1.83e-27	102
k141_86339_1	SARG|gi|664304639|ref|WP_030834011.1|	67.6	74	83	614	1.83e-27	102
k141_86339_1	SARG|gi|1011069317|ref|WP_062010695.1|	67.6	74	83	614	1.83e-27	102
k141_86339_1	SARG|gi|695842130|ref|WP_032755430.1|	67.6	74	83	603	3.39e-27	101
k141_86339_1	SARG|gi|505420018|ref|WP_015607120.1|	67.6	74	83	603	3.39e-27	101
k141_86339_1	SARG|gi|926286457|ref|WP_053623344.1|	67.6	74	83	605	3.40e-27	101
k141_86339_1	SARG|gi|662175949|ref|WP_030118884.1|	67.6	74	83	605	3.40e-27	101
k141_31784_2	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	27.6	152	166	229	1.80e-15	70.1
k141_31784_3	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	48.5	66	69	232	1.18e-12	58.9
k141_31784_3	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	34.8	66	69	231	8.38e-11	53.9
k141_31784_3	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	34.8	66	69	231	8.38e-11	53.9
k141_31784_3	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	34.8	66	69	231	1.16e-10	53.5
k141_31784_3	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	33.3	66	69	231	2.23e-10	52.8
k141_31784_3	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.4	68	69	220	5.41e-09	48.9
k141_31784_3	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	33.3	66	69	231	1.10e-08	48.1
k141_31784_3	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	35.4	65	69	230	1.51e-08	47.8
k141_31784_3	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	30.9	68	69	219	2.73e-08	47.0
k141_31784_3	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	30.9	68	69	219	2.73e-08	47.0
k141_216977_3	megares|MEG_5148|Drugs|beta-lactam|Class_D_betalactamases|OXA_1	27.6	221	272	346	2.10e-17	79.7
k141_178305_2	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	37.1	224	230	228	2.72e-46	152
k141_178305_2	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.7	230	230	231	2.95e-43	144
k141_178305_2	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	37.8	230	230	231	2.95e-43	144
k141_178305_2	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.3	230	230	231	8.29e-43	143
k141_178305_2	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.3	230	230	231	1.65e-42	142
k141_178305_2	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.3	230	230	231	2.33e-42	142
k141_178305_2	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	37.7	231	230	232	1.34e-41	140
k141_178305_2	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	37.7	231	230	232	1.34e-41	140
k141_178305_2	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	37.9	235	230	252	4.54e-41	139
k141_178305_2	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	37.0	230	230	230	7.11e-41	138
k141_178305_3	CARD|gb|AEX49906.1|ARO:3003583|basS	30.8	292	471	477	7.06e-22	97.1
k141_178305_3	CARD|gb|AAD51347.1|ARO:3003067|smeS	33.9	227	471	467	1.61e-21	95.9
k141_178305_5	NCBI|CBE03766.1|1|1|nimB-Cd|nimB-Cd||1|NITROIMIDAZOLE|NITROIMIDAZOLE|putative_5-nitroimidazole_reductase_NimB-Cd|AMR|nitroimidazole	29.8	104	122	155	4.03e-15	66.2
k141_123113_1	NCBI|WP_014936356.1|1|1|tva(B)|tva(B)|target_protection|2|TIAMULIN|PLEUROMUTILIN|ABC-F_type_ribosomal_protection_protein_Tva(B)|AMR|pleuromutilin	30.5	489	493	504	3.63e-67	223
k141_123113_1	SARG|gb|SOX29786.1|ARO:3004730|tva(A)	29.4	504	493	505	2.18e-64	216
k141_123113_1	SARG|gb|ABX00624.1|ARO:3002881|lmrC	31.3	534	493	550	5.79e-48	172
k141_123113_1	SARG|gb|QNR09092.1|ARO:3007042|msr(G)	27.2	474	493	485	1.94e-36	139
k141_123113_1	NCBI|WP_171943877.1|1|1|vga(F)|vga(F)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(F)|AMR|lincosamide	27.0	471	493	461	4.46e-35	135
k141_123113_1	NCBI|WP_172065992.1|1|1|vga(F)|vga(F)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(F)|AMR|lincosamide	26.4	470	493	461	5.51e-34	132
k141_123113_1	SARG|DAC81085.1	25.1	467	493	486	1.24e-32	129
k141_123113_1	SARG|gi|488321355|ref|WP_002390740.1|	27.0	466	493	492	1.33e-32	129
k141_123113_1	CARD|gb|BAB80490.1|ARO:3007644|Cper_cplR	25.7	478	493	568	8.60e-25	106
k141_123113_1	SARG|gb|MBW0764195.1|ARO:3007027|salC	27.3	176	493	541	2.22e-13	71.2
k141_123113_2	CARD|gb|WKR28567.1|ARO:3007678|IreK	32.5	656	661	718	4.55e-85	281
k141_344072_1	SARG|gi|445983949|ref|WP_000061804.1|	31.0	168	211	492	7.55e-11	59.7
k141_344072_1	SARG|gi|1008988570|ref|WP_061884457.1|	29.8	168	211	492	1.38e-10	58.9
k141_344072_1	SARG|gi|765018624|ref|WP_044584737.1|	29.8	168	211	492	1.86e-10	58.5
k141_344072_1	SARG|gi|445983935|ref|WP_000061790.1|	29.8	168	211	492	1.86e-10	58.5
k141_344072_1	SARG|gi|445983943|ref|WP_000061798.1|	29.8	168	211	492	1.86e-10	58.5
k141_344072_1	SARG|gi|1005558399|ref|WP_061655514.1|	29.8	168	211	492	1.86e-10	58.5
k141_344072_1	SARG|gi|445983944|ref|WP_000061799.1|	29.8	168	211	492	1.86e-10	58.5
k141_344072_1	SARG|gi|657632362|ref|WP_029442980.1|	31.0	168	211	492	2.52e-10	58.2
k141_344072_1	SARG|gi|558693259|ref|WP_023522676.1|	31.0	168	211	492	2.52e-10	58.2
k141_344072_1	SARG|gi|1024915484|ref|WP_063548266.1|	31.0	168	211	492	2.52e-10	58.2
k141_69637_3	NCBI|WP_109545033.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	30.3	254	415	355	4.26e-21	92.8
k141_69637_3	megares|MEG_7602|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	30.3	254	415	355	4.26e-21	92.8
k141_69637_3	SARG|ACM47285	30.3	254	415	363	4.65e-21	92.8
k141_69637_3	NCBI|WP_049898469.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	29.7	256	415	356	1.08e-20	91.7
k141_69637_3	NCBI|WP_063856862.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	29.7	256	415	356	1.46e-20	91.3
k141_13936_3	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	23.5	247	341	574	6.05e-12	65.5
k141_13936_4	SARG|gi|981224618|ref|WP_059445588.1|	31.2	234	387	646	2.12e-25	107
k141_13936_4	SARG|gi|836585048|ref|WP_047742322.1|	31.2	234	387	646	2.12e-25	107
k141_13936_4	SARG|gi|1016275448|gb|AMX06027.1|	30.8	234	387	646	2.85e-25	106
k141_13936_4	SARG|gi|779866095|ref|WP_045354445.1|	30.8	234	387	646	3.84e-25	106
k141_13936_4	SARG|gi|895872463|ref|WP_048979698.1|	30.8	234	387	646	3.84e-25	106
k141_13936_4	SARG|gi|751930065|ref|WP_041144773.1|	31.6	234	387	648	3.85e-25	106
k141_13936_4	SARG|gi|556487375|ref|WP_023335108.1|	30.8	234	387	646	5.17e-25	105
k141_13936_4	SARG|gi|779956086|ref|WP_045403603.1|	30.8	234	387	646	5.17e-25	105
k141_13936_4	SARG|gi|695731723|ref|WP_032658224.1|	30.8	234	387	646	5.17e-25	105
k141_13936_4	SARG|gi|1016942913|ref|WP_063144441.1|	30.8	234	387	646	5.17e-25	105
k141_218683_3	SARG|gi|823326845|ref|WP_047080664.1|	43.9	57	80	648	1.25e-06	43.1
k141_218683_3	SARG|gi|695793471|ref|WP_032707680.1|	43.9	57	80	648	1.25e-06	43.1
k141_218683_3	SARG|gi|823302270|ref|WP_047057473.1|	43.9	57	80	648	1.25e-06	43.1
k141_218683_3	SARG|gi|976146774|ref|WP_059305359.1|	43.9	57	80	648	1.25e-06	43.1
k141_218683_3	SARG|gi|1022664304|ref|WP_063420886.1|	43.9	57	80	648	1.25e-06	43.1
k141_218683_3	SARG|gi|1022688710|ref|WP_063443532.1|	43.9	57	80	648	1.25e-06	43.1
k141_218683_3	SARG|gi|823309640|ref|WP_047064288.1|	43.9	57	80	648	1.25e-06	43.1
k141_218683_3	SARG|gi|505807117|ref|WP_015704872.1|	43.9	57	80	648	1.25e-06	43.1
k141_218683_3	SARG|gi|505180394|ref|WP_015367496.1|	43.9	57	80	648	1.25e-06	43.1
k141_218683_3	SARG|gi|518923394|ref|WP_020079269.1|	43.9	57	80	648	1.25e-06	43.1
k141_88721_1	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	33.7	315	319	343	7.38e-49	165
k141_88721_1	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	33.8	314	319	325	8.26e-41	144
k141_88721_1	SARG|gb|AAA26793|ARO:3003748|oleC	33.7	312	319	325	2.27e-40	142
k141_88721_1	SARG|gb|AAR96051.1|ARO:3002894|otrC	31.3	319	319	351	3.43e-29	113
k141_88721_1	megares|MEG_4383|Drugs|Tetracycline|Tetracycline_resistance_ABC_efflux_pumps|OTRC_1	31.0	319	319	351	2.42e-28	111
k141_88721_1	SARG|gb|ADZ12699.1|ARO:3005091|RanA	27.8	216	319	258	5.45e-21	89.4
k141_88721_1	SARG|gb|AAK76137.1|ARO:3000024|patA	27.9	208	319	564	3.80e-17	80.9
k141_88721_1	SARG|gi|514904648|ref|WP_016630030.1|	26.1	180	319	498	1.45e-08	54.7
k141_88721_1	SARG|gi|498397844|ref|WP_010711245.1|	25.6	180	319	498	3.43e-08	53.5
k141_88721_1	SARG|gb|APB03219.1|ARO:3003986|TaeA	23.3	232	319	648	3.86e-08	53.5
k141_15392_2	megares|MEG_7170|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	26.8	369	541	629	1.40e-19	91.3
k141_15392_2	SARG|gi|1004359922|gb|AMP42228.1|	26.6	364	541	639	1.42e-19	91.3
k141_15392_2	ResF|tet(O/W)_4_AM889121_1	26.8	369	541	639	1.42e-19	91.3
k141_15392_2	SARG|ACI02041	26.6	364	541	639	1.89e-19	90.9
k141_15392_2	megares|MEG_7163|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	27.0	371	541	629	3.27e-19	90.1
k141_15392_2	SARG|gi|1004359892|gb|AMP42199.1|	26.9	364	541	639	3.33e-19	90.1
k141_15392_2	ResF|tet(O/W)_5_AM889122_1	27.0	371	541	639	3.33e-19	90.1
k141_15392_2	SARG|CAO78565	26.9	364	541	639	3.33e-19	90.1
k141_15392_2	SARG|WP_000691721.1	26.6	364	541	639	4.41e-19	89.7
k141_15392_2	SARG|gi|104303742|gb|ABF72138.1|	26.6	364	541	639	4.41e-19	89.7
k141_16002_2	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.1	234	422	381	5.04e-26	107
k141_16002_2	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	29.1	234	422	381	5.04e-26	107
k141_16002_2	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	28.4	232	422	370	3.40e-24	102
k141_16002_2	megares|MEG_7497|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	28.6	231	422	376	6.79e-24	101
k141_16002_2	NCBI|WP_034869172.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	28.6	231	422	376	6.79e-24	101
k141_16002_2	megares|MEG_7501|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	27.9	229	422	354	3.30e-23	99.0
k141_16002_2	megares|MEG_7500|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	28.1	231	422	352	4.38e-23	98.6
k141_16002_2	megares|MEG_7503|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	27.7	231	422	354	1.13e-22	97.4
k141_16002_2	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.1	235	422	381	9.67e-22	95.1
k141_16002_2	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.1	235	422	381	9.67e-22	95.1
k141_363059_4	SARG|gb|APB03219.1|ARO:3003986|TaeA	28.5	239	318	648	6.90e-10	58.9
k141_363059_5	SARG|gi|671541568|ref|WP_031525212.1|	31.8	239	285	648	1.40e-22	96.3
k141_363059_5	SARG|gi|504542119|ref|WP_014729221.1|	34.4	221	285	647	6.32e-22	94.4
k141_363059_5	SARG|gi|742378414|ref|WP_038857601.1|	34.4	221	285	647	6.32e-22	94.4
k141_363059_5	SARG|gi|696411918|ref|WP_032982657.1|	33.9	227	285	647	8.55e-22	94.0
k141_363059_5	SARG|gi|851913025|ref|WP_048215946.1|	32.8	229	285	648	8.56e-22	94.0
k141_363059_5	SARG|gi|489930965|ref|WP_003834285.1|	32.8	229	285	648	8.56e-22	94.0
k141_363059_5	SARG|YP_001438541	34.4	221	285	647	1.16e-21	93.6
k141_363059_5	SARG|gi|938461734|ref|WP_054625806.1|	34.4	221	285	647	1.16e-21	93.6
k141_363059_5	SARG|gi|938460528|ref|WP_054624864.1|	34.4	221	285	647	1.16e-21	93.6
k141_363059_5	SARG|gi|1020141879|ref|WP_063264839.1|	34.4	221	285	647	1.16e-21	93.6
k141_272814_2	SARG|gb|AAK76136.1|ARO:3000025|patB	34.5	574	592	588	2.07e-92	295
k141_272814_2	SARG|gb|CDO61516.1|ARO:3003949|efrB	52.2	299	592	362	1.01e-89	280
k141_272814_2	SARG|gb|AYV52072.1|ARO:3002882|lmrD	36.1	487	592	664	1.67e-87	284
k141_272814_2	SARG|gi|648667297|ref|WP_026359044.1|	33.9	584	592	605	3.32e-86	279
k141_272814_2	SARG|gi|944009777|ref|WP_055601444.1|	36.2	511	592	628	4.10e-86	279
k141_272814_2	SARG|gi|1033217078|gb|OAR27197.1|	35.3	498	592	601	4.22e-86	278
k141_272814_2	SARG|gi|917229923|ref|WP_051836635.1|	36.6	497	592	620	4.75e-86	279
k141_272814_2	SARG|gi|516795764|ref|WP_018105258.1|	36.1	509	592	601	5.91e-86	278
k141_272814_2	SARG|gi|860594225|ref|WP_048475168.1|	34.6	584	592	620	6.65e-86	278
k141_272814_2	SARG|gi|496018010|ref|WP_008742581.1|	36.4	497	592	623	1.00e-85	278
k141_363724_5	SARG|gi|936194420|ref|WP_054528571.1|	47.7	222	222	648	4.65e-57	190
k141_363724_5	SARG|gi|696361545|ref|WP_032936694.1|	47.3	224	222	648	1.75e-56	188
k141_363724_5	SARG|gi|489936909|ref|WP_003840216.1|	47.3	224	222	648	1.75e-56	188
k141_363724_5	SARG|gi|507079862|ref|WP_016150620.1|	47.3	224	222	648	1.75e-56	188
k141_363724_5	SARG|gi|949791377|ref|WP_057104572.1|	47.3	224	222	648	1.75e-56	188
k141_363724_5	SARG|gi|851922185|ref|WP_048218206.1|	47.3	224	222	648	9.17e-56	186
k141_363724_5	SARG|gi|949718947|ref|WP_057063453.1|	47.3	224	222	648	9.17e-56	186
k141_363724_5	SARG|gi|696375069|ref|WP_032949617.1|	47.3	224	222	648	9.17e-56	186
k141_363724_5	SARG|gi|489127020|ref|WP_003036815.1|	47.3	224	222	648	9.17e-56	186
k141_363724_5	SARG|gi|835233765|ref|WP_047410073.1|	46.9	224	222	648	1.78e-55	186
k141_363910_3	SARG|YP_001779894	36.4	118	194	212	5.36e-16	72.0
k141_363910_3	SARG|YP_002861121	35.3	119	194	212	1.04e-15	71.2
k141_363910_3	SARG|YP_001389621	35.6	118	194	212	1.44e-15	70.9
k141_363910_3	SARG|YP_001785579	35.6	118	194	212	2.79e-15	70.1
k141_363910_3	SARG|U19459.gene.p01	34.7	118	194	212	1.44e-14	68.2
k141_363910_3	SARG|GQ205627.2.gene3.p01	33.3	120	194	216	2.95e-14	67.4
k141_363910_3	NCBI|WP_031281281.1|1|1|catB|catB|acetyltransferase|2|CHLORAMPHENICOL|PHENICOL|type_B_phenicol_O-acetyltransferase|AMR|phenicol	37.8	82	194	210	3.74e-14	67.0
k141_363910_3	SARG|AF015628.1.gene2.p01	37.2	113	194	212	3.86e-14	67.0
k141_363910_3	SARG|AF418284.1.gene3.p01	37.8	82	194	210	9.99e-14	65.9
k141_363910_3	SARG|AJ223604.1.gene5.p01	35.4	82	194	210	9.99e-14	65.9
k141_90844_1	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	46.5	226	239	228	2.15e-64	199
k141_90844_1	CARD|gb|AAD51348.1|ARO:3003066|smeR	43.9	223	239	229	6.06e-59	185
k141_90844_1	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	43.0	230	239	232	1.88e-58	184
k141_90844_1	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	43.0	230	239	232	1.88e-58	184
k141_90844_1	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	42.8	229	239	231	2.08e-57	181
k141_90844_1	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	42.7	225	239	232	4.28e-57	180
k141_90844_1	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	41.5	241	239	252	1.10e-56	180
k141_90844_1	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	42.4	224	239	231	4.72e-56	177
k141_90844_1	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	42.8	229	239	231	1.34e-55	176
k141_90844_1	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	42.8	229	239	231	1.89e-55	176
k141_164157_2	SARG|gi|974672242|ref|WP_059256507.1|	38.0	221	266	648	5.45e-37	137
k141_164157_2	SARG|gi|974641719|ref|WP_059227752.1|	38.0	221	266	648	5.45e-37	137
k141_164157_2	SARG|gi|446110299|ref|WP_000188154.1|	38.0	221	266	648	5.45e-37	137
k141_164157_2	SARG|ZP_02903696	38.0	221	266	648	5.45e-37	137
k141_164157_2	SARG|gi|974688082|ref|WP_059271287.1|	38.0	221	266	648	5.45e-37	137
k141_164157_2	SARG|gi|446110301|ref|WP_000188156.1|	38.5	221	266	648	7.48e-37	136
k141_164157_2	SARG|gi|693106883|ref|WP_032260279.1|	38.5	221	266	648	1.40e-36	135
k141_164157_2	SARG|gi|643601187|ref|WP_025237288.1|	37.6	221	266	648	1.93e-36	135
k141_164157_2	SARG|gi|974628291|ref|WP_059215695.1|	37.6	221	266	648	1.93e-36	135
k141_164157_2	SARG|gi|446110298|ref|WP_000188153.1|	37.6	221	266	648	1.93e-36	135
k141_328841_2	SARG|gi|763399392|ref|WP_044256358.1|	38.6	236	234	648	7.16e-49	168
k141_328841_2	SARG|gi|823326845|ref|WP_047080664.1|	41.3	230	234	648	1.91e-48	167
k141_328841_2	SARG|gi|754964360|ref|WP_042320280.1|	40.8	218	234	648	2.64e-48	167
k141_328841_2	SARG|gi|976146774|ref|WP_059305359.1|	40.9	232	234	648	2.64e-48	167
k141_328841_2	SARG|gi|505807117|ref|WP_015704872.1|	40.9	232	234	648	2.64e-48	167
k141_328841_2	SARG|gi|695797094|ref|WP_032711285.1|	40.9	232	234	648	2.64e-48	167
k141_328841_2	SARG|gi|823299155|ref|WP_047054544.1|	40.9	232	234	648	2.64e-48	167
k141_328841_2	SARG|gi|757782629|ref|WP_043001213.1|	38.6	236	234	648	3.66e-48	166
k141_328841_2	SARG|gi|823302270|ref|WP_047057473.1|	41.3	230	234	648	3.66e-48	166
k141_328841_2	SARG|gi|1022664304|ref|WP_063420886.1|	41.3	230	234	648	3.66e-48	166
k141_108652_2	SARG|gb|APB03219.1|ARO:3003986|TaeA	26.2	267	276	648	4.12e-11	62.0
k141_383710_6	SARG|FJ349556.1.gene5.p01	34.2	234	318	326	2.17e-32	121
k141_383710_6	SARG|AAR37059	34.5	235	318	323	1.07e-31	119
k141_383710_6	SARG|AAD41881	34.5	235	318	323	1.07e-31	119
k141_383710_6	SARG|DQ018711.1.gene4.p01	32.5	240	318	322	2.83e-31	118
k141_383710_6	SARG|gi|738848198|ref|WP_036737307.1|	33.8	240	318	323	2.88e-31	118
k141_383710_6	SARG|AAD51059	34.6	237	318	323	2.88e-31	118
k141_383710_6	SARG|gi|746609237|ref|WP_039635344.1|	32.5	255	318	322	7.62e-31	117
k141_383710_6	SARG|AAD42183	35.0	237	318	322	1.06e-30	117
k141_383710_6	SARG|gi|737310392|ref|WP_035293250.1|	32.5	240	318	323	1.08e-30	117
k141_383710_6	SARG|gi|552942232|ref|WP_023043160.1|	34.9	235	318	323	1.50e-30	116
k141_201543_1	SARG|gb|AAC75271.1|ARO:3003952|yojI	27.7	184	270	547	8.56e-11	60.8
k141_310825_1	SARG|gi|951183771|ref|WP_057661487.1|	68.6	35	48	603	1.61e-09	49.7
k141_310825_1	SARG|gi|695887424|ref|WP_032788534.1|	68.6	35	48	605	1.61e-09	49.7
k141_310825_1	SARG|gi|497748188|ref|WP_010062372.1|	68.6	35	48	605	1.61e-09	49.7
k141_310825_1	SARG|gi|764446018|ref|WP_044369325.1|	68.6	35	48	605	1.61e-09	49.7
k141_310825_1	SARG|gi|695865802|ref|WP_032778631.1|	68.6	35	48	605	1.61e-09	49.7
k141_310825_1	SARG|gi|1045390184|ref|WP_065479071.1|	68.6	35	48	605	1.61e-09	49.7
k141_310825_1	SARG|gi|664180077|ref|WP_030714054.1|	68.6	35	48	605	1.61e-09	49.7
k141_310825_1	SARG|gi|664352659|ref|WP_030880307.1|	62.9	35	48	601	3.02e-09	48.9
k141_310825_1	SARG|gi|662754041|ref|WP_030125200.1|	62.9	35	48	601	3.02e-09	48.9
k141_310825_1	SARG|gi|664100597|ref|WP_030638327.1|	62.9	35	48	601	3.02e-09	48.9
k141_109540_1	SARG|AAZ79478	42.5	146	598	657	5.96e-26	111
k141_109540_1	SARG|BAD46890	42.5	146	598	657	5.96e-26	111
k141_109540_1	megares|MEG_7181|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	42.5	146	598	657	5.96e-26	111
k141_109540_1	SARG|Z21523.gene.p01	42.5	146	598	657	5.96e-26	111
k141_109540_1	megares|MEG_7182|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	42.5	146	598	670	6.18e-26	111
k141_109540_1	SARG|AAB51122	42.5	146	598	670	6.18e-26	111
k141_109540_1	SARG|ZP_04557016	40.1	172	598	657	7.93e-26	111
k141_109540_1	SARG|AM180355.1.gene636.p01	41.4	140	598	639	6.69e-22	99.0
k141_414556_1	NCBI|XSG12257.1|1|1|drcB|drcB||1|||daptomycin_efflux_ABC_transporter_permease_DrcB|AMR|peptide	26.5	298	722	641	2.68e-18	88.2
k141_414556_2	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	54.3	254	255	255	3.75e-93	273
k141_414556_2	SARG|gi|740856590|ref|WP_038641842.1|	40.8	223	255	648	1.36e-46	163
k141_414556_2	SARG|gi|922960663|ref|WP_053388845.1|	40.8	223	255	648	1.88e-46	162
k141_414556_2	SARG|gi|757799695|ref|WP_043016897.1|	40.8	223	255	648	2.60e-46	162
k141_414556_2	SARG|gi|1045891604|ref|WP_065554100.1|	40.8	223	255	648	2.60e-46	162
k141_414556_2	SARG|gi|507082903|ref|WP_016153652.1|	40.8	223	255	648	2.60e-46	162
k141_414556_2	SARG|gi|835233765|ref|WP_047410073.1|	40.1	247	255	648	2.60e-46	162
k141_414556_2	SARG|gi|1032819400|ref|WP_064325534.1|	40.4	225	255	646	4.88e-46	161
k141_414556_2	SARG|gi|696368937|ref|WP_032943949.1|	40.8	223	255	648	4.98e-46	161
k141_414556_2	SARG|gi|754951242|ref|WP_042307417.1|	40.8	223	255	648	4.98e-46	161
k141_275324_2	SARG|gb|WP_104671188.1|ARO:3003948|efrA	38.9	548	577	575	3.70e-112	345
k141_275324_2	SARG|gb|AAK76137.1|ARO:3000024|patA	30.3	518	577	564	3.27e-72	240
k141_275324_2	SARG|gi|1033217078|gb|OAR27197.1|	29.7	575	577	601	4.12e-60	209
k141_275324_2	SARG|gi|739906046|ref|WP_037756452.1|	29.5	569	577	620	1.54e-59	207
k141_275324_2	SARG|gi|664556405|ref|WP_031071225.1|	30.2	573	577	602	2.98e-59	206
k141_275324_2	SARG|gi|517381192|ref|WP_018555350.1|	29.4	585	577	602	4.12e-59	206
k141_275324_2	SARG|gi|985844137|ref|WP_060895163.1|	30.1	562	577	599	7.50e-59	205
k141_275324_2	SARG|gi|1045390184|ref|WP_065479071.1|	30.2	573	577	605	8.35e-59	205
k141_275324_2	SARG|gi|516574297|ref|WP_017949361.1|	29.5	569	577	620	1.08e-58	205
k141_275324_2	SARG|gi|943909899|ref|WP_055545300.1|	29.9	569	577	601	1.49e-58	204
k141_417544_2	SARG|gb|APB03219.1|ARO:3003986|TaeA	37.1	566	616	648	6.05e-103	325
k141_417544_2	SARG|U82085.gene.p01	27.3	527	616	552	3.12e-49	179
k141_417544_2	SARG|gb|QQA64075.1|ARO:3007043|msr(I)	27.8	514	616	485	6.44e-49	176
k141_417544_2	NCBI|AJP12342.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	28.7	502	616	550	1.08e-48	177
k141_417544_2	NCBI|WP_000420317.1|1|1|msr(D)|msr(D)|target_protection|2|AZITHROMYCIN/ERYTHROMYCIN/STREPTOGRAMIN_B|MACROLIDE/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_Msr(D)|AMR|multidrug	28.8	513	616	487	1.27e-48	176
k141_417544_2	NCBI|WP_000420313.1|1|1|msr(D)|msr(D)|target_protection|2|AZITHROMYCIN/ERYTHROMYCIN/STREPTOGRAMIN_B|MACROLIDE/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_Msr(D)|AMR|multidrug	28.7	513	616	487	4.59e-48	174
k141_417544_2	NCBI|WP_000052512.1|1|1|msr(E)|msr(E)|target_protection|2|AZITHROMYCIN/ERYTHROMYCIN/STREPTOGRAMIN|MACROLIDE/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_Msr(E)|AMR|multidrug	28.0	511	616	491	1.21e-46	170
k141_417544_2	SARG|gb|QNR09092.1|ARO:3007042|msr(G)	29.0	514	616	485	7.34e-46	168
k141_417544_2	SARG|gi|488231473|ref|WP_002302681.1|	30.5	502	616	492	2.16e-45	167
k141_417544_2	SARG|gi|488216250|ref|WP_002287458.1|	30.5	502	616	492	2.16e-45	167
